Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.49 |
| ▸ | PPARA | Q07869 | 8/20 | 0.43 |
| ▸ | PPARD | Q03181 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10169077 | 0.81 | HRH3 (0.48) | HRH3PPARAPPARDNPC1RAB9A | |
| SCHEMBL10169042 | 0.79 | PLOD2 (0.47) | HRH3PPARAPPARDNPC1RAB9A | |
| SCHEMBL10211665 | 0.79 | HRH3 (0.48) | HRH3PPARAPPARDNPC1RAB9A | |
| SCHEMBL10168947 | 0.78 | SMYD3 (0.55) | HRH3NPC1RAB9ASMN1; SMN2USP30 | |
| SCHEMBL13051465 | 0.78 | L3MBTL1 (0.64) | NPC1RAB9A | |
| SCHEMBL10212614 | 0.78 | GRM5 (0.62) | HRH3USP30KMT2A | |
| SCHEMBL10210766 | 0.77 | HRH3 (0.58) | HRH3USP30 | |
| SCHEMBL10168938 | 0.77 | USP30 (0.52) | HRH3NPC1RAB9AUSP30 | |
| SCHEMBL10168929 | 0.77 | USP30 (0.66) | HRH3PPARAPPARDNPC1RAB9A | |
| SCHEMBL10168946 | 0.77 | HRH3 (0.52) | HRH3NPC1RAB9AUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586751-B2 | Nicotinamide compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | HRH3 1169/4885PPARA 1681/4885PPARD 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.